Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?

被引:89
作者
Guckenberger, Matthias [1 ]
Kestin, Larry L. [2 ]
Hope, Andrew J. [3 ]
Belderbos, Jose [4 ]
Werner-Wasik, Maria [5 ]
Yan, Di [2 ]
Sonke, Jan-Jakob [4 ]
Bissonnette, Jean Pierre [3 ]
Wilbert, Juergen [1 ]
Xiao, Ying [5 ]
Grills, Inga S. [2 ]
机构
[1] Univ Hosp Wuerzburg, Dept Radiat Oncol, D-97080 Wurzburg, Germany
[2] William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI USA
[3] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[4] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[5] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
关键词
Non-small cell lung cancer; Stereotactic body radiotherapy; Pulmonary function; AIR-FLOW OBSTRUCTION; RADIATION-THERAPY; CAPACITY PREDICTS; NATURAL-HISTORY; SURVIVAL; TIME; SEGMENTECTOMY; LOBECTOMY; RESECTION; DYSPNEA;
D O I
10.1097/JTO.0b013e31824165d7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: To evaluate the influence of pretreatment pulmonary function (PF) on survival, early and late pulmonary toxicity after stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer. Methods: Four hundred eighty-three patients with 505 tumors of early-stage non-small cell lung cancer cT1-3 cN0 were treated with image-guided SBRT at five international institutions (1998-2010). Sixty-four percent of the tumors were biopsy-proven and 18F-fluorodeoxyglucose-positron emission tomography was performed for staging in 84%. Image-guided SBRT was performed with a median of three fractions to a median total dose of 54 Gy. Pretreatment PF was available for 423 patients, and 617 posttreatment PF tests from 270 patients were available. Results: A large variability of pretreatment PF was observed: the 90% range of forced expiratory volume in 1 second and diffusing capacity for carbon monoxide was 29 to 109% and 5.5 to 19.1 ml/min/mmHg, respectively. PF was significantly correlated with overall survival but not cause-specific survival: diffusing capacity for carbon monoxide of 11.2 ml/min/mmHg differentiated between 3-year overall survival of 66% and 42%. Radiation-induced pneumonitis grade >= II occurred in 7% of patients and was not increased in patients with lower PF. A significant and progressive change of PF was observed after SBRT: PF decreased by 3.6% and 6.8% on average within 6 and 6 to 24 months after SBRT, respectively. Changes of PF after SBRT were significantly correlated with pretreatment PF: PF improved for worst pretreatment PF and the largest loss was observed for best pretreatment PF. Conclusions: Image-guided SBRT is safe in terms of acute and chronic pulmonary toxicity even for patients with severe pulmonary comorbidities. SBRT should be considered as a curative treatment option for inoperable patients with pretreatment PF as reported in this study.
引用
收藏
页码:542 / 551
页数:10
相关论文
共 38 条
  • [1] [Anonymous], 1995, Ann. Thorac. Surg, DOI 10.1016/0003-4975
  • [2] [Anonymous], 2001, Cochrane Database Syst Rev, DOI DOI 10.1002/14651858.CD002935
  • [3] Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study
    Baumann, Pia
    Nyman, Jan
    Hoyer, Morten
    Gagliardi, Giovanna
    Lax, Ingmar
    Wennberg, Berit
    Drugge, Ninni
    Ekberg, Lars
    Friesland, Signe
    Johansson, Karl-Axel
    Lund, Jo-Asmund
    Morhed, Elisabeth
    Nilsson, Kristina
    Levin, Nina
    Paludan, Merete
    Sederholm, Christer
    Traberg, Anders
    Wittgren, Lena
    Lewensohn, Rolf
    [J]. RADIOTHERAPY AND ONCOLOGY, 2008, 88 (03) : 359 - 367
  • [4] Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy
    Baumann, Pia
    Nyman, Jan
    Hoyer, Morten
    Wennberg, Berit
    Gagliardi, Giovanna
    Lax, Ingmar
    Drugge, Ninni
    Ekberg, Lars
    Friesland, Signe
    Johansson, Karl-Axel
    Lund, Jo-Asmund
    Morhed, Elisabeth
    Nilsson, Kristina
    Levin, Nina
    Paludan, Merete
    Sederholm, Christer
    Traberg, Anders
    Wittgren, Lena
    Lewensohn, Rolf
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3290 - 3296
  • [5] PROSPECTIVE, RISK-ADAPTED STRATEGY OF STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER: RESULTS OF A PHASE II TRIAL
    Bral, Samuel
    Gevaert, Thierry
    Linthout, Nadine
    Versmessen, Harijati
    Collen, Christine
    Engels, Benedikt
    Verdries, Douwe
    Everaert, Hendrik
    Christian, Nicolas
    De Ridder, Mark
    Storme, Guy
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (05): : 1343 - 1349
  • [6] The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease
    Celli, BR
    Cote, CG
    Marin, JM
    Casanova, C
    de Oca, MM
    Mendez, RA
    Pinto Plata, V
    Cabral, HJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (10) : 1005 - 1012
  • [7] Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors
    Collins, Brian T.
    Erickson, Kelly
    Reichner, Cristina A.
    Collins, Sean P.
    Gagnon, Gregory J.
    Dieterich, Sonja
    McRae, Don A.
    Zhang, Ying
    Yousefi, Shadi
    Levy, Elliot
    Chang, Thomas
    Jamis-Dow, Carlos
    Banovac, Filip
    Anderson, Eric D.
    [J]. RADIATION ONCOLOGY, 2007, 2 (1)
  • [8] STEREOTACTIC BODY RADIATION THERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CARCINOMA: FOUR-YEAR RESULTS OF A PROSPECTIVE PHASE II STUDY
    Fakiris, Achilles J.
    McGarry, Ronald C.
    Yiannoutsos, Constantin T.
    Papiez, Lech
    Williams, Mark
    Henderson, Mark A.
    Timmerman, Robert
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : 677 - 682
  • [9] FERGUSON MK, 1988, J THORAC CARDIOV SUR, V96, P894
  • [10] Fishman A, 2003, NEW ENGL J MED, V348, P2059